You are here

Amgen Terminates Study of Ganitumab in Metastatic Pancreatic Cancer

Drug was unlikely to improve overall survival when combined with gemcitabine

Based on the review of a preplanned interim analysis, the DMC concluded that the addition of ganitumab (AMG 479) to gemcitabine was unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared with gemcitabine alone.

The GAMMA study was conducted to determine whether ganitumab plus gemcitabine improves overall survival compared with placebo plus gemcitabine in the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

Amgen is notifying study investigators that treatment with ganitumab should be discontinued in the GAMMA trial, as well as in a separate ongoing phase II study in locally advanced pancreatic cancer.

Ganitumab is an investigational fully human monoclonal antibody that targets the type-1 insulin-like growth factor receptor (IGF1R).

For more information, visit the Amgen Web Site.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs